PROTAC CYP1B1 degrader-1

PROTAC CYP1B1 degrader-1 (Compound 6C), a α-naphthoflavone chimera derivative, is able to eliminate cytochrome P450 (CYP) 1B1-mediated agent resistance via targeted CYP1B1 degradation, with IC50s of 95.1 and 9838.6 nM for CYP1B1 and CYP1A2, respectively. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-overexpressing prostate cancer[1].

Product Specifications

CAS Number

[2411389-67-6]

UNSPSC

12352005

Target

Cytochrome P450; PROTACs

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/protac-cyp1b1-degrader-1.html

Purity

98.09

Solubility

DMF : 10 mg/mL (ultrasonic)

Smiles

COC1=CC=C(C2=C3OC(C4=CC=C(C=C4)C5=CN(N=N5)CCCCCCOC6=CC=CC7=C6C(N(C7=O)C8CCC(NC8=O)=O)=O)=CC(C3=CC(OC)=C12)=O)OC

Molecular Formula

C43H39N5O10

Molecular Weight

785.80

References & Citations

[1]Li Zhou, et al. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP) 1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur J Med Chem. 2020 Mar 1;189:112028.